> ## Content Index
> Fetch the complete content index at: https://www.fdaweb.com/llms.txt
> Use this file to discover other available public pages before exploring further.

# House Subcommittee OKs $257 Million FDA Boost
- URL: https://www.fdaweb.com/house-subcommittee-oks-257-million-fda-boost/
- Published: 2021-06-25T12:00:00.000Z
- Updated: 2026-09-14T17:04:52.000Z
- Author: David McFarland
- Tags: FDA Policy/General, #legacy-id-D5149626

The House Appropriations Subcommittee on Agriculture, Rural Development, Food and Drug Administration, and Related Agencies 6/25 has approved by voice vote FDA’s s fiscal year 2022 budget bill. Under the measure, the agency would receive $3.471 billion in discretionary funding in the bill, an increase of $257 million (8%) above the FY 2021 enacted level.

“Total funding for FDA, including revenue from user fees, is $6.288 billion,” a [committee notice](https://appropriations.house.gov/news/press-releases/appropriations-subcommittee-approves-fiscal-year-2022-agriculture-rural?ref=fdaweb.com) says. “Within this total, the committee provides a targeted increase of $72 million to address the opioid crisis, medical supply chain surveillance, rare cancers, and increasing and strengthening inspections. It also includes a $65 million increase to better avoid or more quickly respond to food outbreaks, improve the animal food inspection system, and addresses heavy metals in baby food. The bill also appropriates $50 million to accelerate medical product development as authorized in the 21st Century Cures Act.”

The Alliance for a Stronger FDA had this to say: “We are grateful for the House’s support of FDA and appreciate that its proposed increase in BA funding will go a long way toward addressing the agency’s many resource needs. In any year, a $257 million/8% increase for FDA is substantial and meaningful. For that, we thank the members of the House subcommittee. We will work with the Senate to achieve a similarly large commitment to FDA’s FY 22 funding needs. The drive to strengthen the FDA is a multi-year marathon, not a sprint, and the Alliance will continue to advocate for critical funding to strengthen the agency.”